Physician profile
Ali M Dohan
NPI 1558457432
$10,116.16
in general payments reported to CMS, 2019-2025
44 companies · $569 in 2025
The $569 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,093 · 2020: $1,760 · 2021: $2,437 · 2022: $1,501 · 2023: $876 · 2024: $880 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,325.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,431.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,218.30 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,069.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $893.50 | 2019-2024 | Vraylar, Linzess, Viberzi |
| Lilly USA, LLC | $777.33 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $739.54 | 2019-2024 | Evenity, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $450.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.63 | 2020-2023 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $315.42 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $315.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $272.71 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $256.85 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $249.64 | 2019-2021 | |
| Allergan, INC. | $248.80 | 2019-2020 | |
| Amarin Pharma, INC. | $205.54 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Dohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.